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OBJECTIVES This study was designed to examine a unique and low dose of intravenous enoxaparin in
elective percutaneous coronary intervention (PCI) that would be applicable to an unselected
population regardless of age, weight, renal function, or use of glycoprotein IIb/IIIa inhibitors.
BACKGROUND There is limited experience of anticoagulation using intravenous (IV) low-molecular-weight
heparin in PCI, which has been obtained with high doses causing elevated anticoagulation
levels and delayed sheath withdrawal.
METHODS A total of 242 consecutive patients undergoing elective PCI were treated with a single IV
bolus of enoxaparin (0.5 mg/kg), and 26% of patients (n  64) also received eptifibatide.
Sheaths were removed immediately after the procedure in patients treated with enoxaparin
only, and 4 h after the procedure in those also treated with eptifibatide.
RESULTS A peak anti-Xa 0.5 IU/ml was obtained in 97.5% of the population, and 94.6% of patients
had their peak anti-Xa level in the predefined target range of 0.5 to 1.5 IU/ml. Advanced age,
renal failure, being overweight, and eptifibatide use did not alter the anticoagulation profile.
At one-month follow-up, six patients (2.5%) had died, had a myocardial infarction, or
undergone an urgent revascularization; all the patients had an anti-Xa level 0.5 IU/ml
during PCI. Patients without an ischemic event and without a creatine kinase rise, but with
a detectable troponin release in the next 24 h of PCI (2 g/ml, n 21), had similar anti-Xa
levels as those without troponin elevation. There were one major and three minor bleeding
events that were not associated with anti-Xa overshoot.
CONCLUSIONS Low-dose (0.5 mg/kg) IV enoxaparin allows a prespecified target level of anticoagulation
(anti-Xa 0.5 IU/ml) in the vast majority of patients undergoing PCI, appears to be safe and
effective, allows immediate sheath removal when used alone, and does not require dose
adjustment when used with eptifibatide. (J Am Coll Cardiol 2002;40:1943–50) © 2002 by
the American College of Cardiology Foundation
Subcutaneous enoxaparin has shown its superiority over
unfractionated heparin (UFH) in the medical treatment of
unstable angina (UA) and non–ST-elevation myocardial
infarction (NSTEMI) (1,2). Recent studies have also shown
good results with subcutaneous enoxaparin anticoagulation
of patients with UA/NSTEMI undergoing percutaneous
coronary intervention (PCI) on such subcutaneous enoxapa-
rin treatment (3–5). Although PCI has improved dramati-
cally because of innovations in techniques, stents, and
antiplatelet agents, the optimal anticoagulant treatment
remains uncertain. Low doses of UFH are currently recom-
mended, especially if glycoprotein (GP) IIb/IIIa inhibitors
are also being used (6–8). Intravenous (IV) low-molecular-
weight heparins (LMWH) in elective PCI have been
evaluated in various registries recruiting patients not pre-
treated by LMWH before the catheterization laboratory
(9–11).
Kereiakes et al. (10) tested two different doses of the
LMWH dalteparin used concomitantly with the GP IIb/
IIIa inhibitor abciximab, and the National Investigators
Collaborating on Enoxaparin (NICE)-4 and -1 studies
tested two different doses of enoxaparin with and without
concomitant use of abciximab (11). In the NICE-1 and
NICE-4 studies, mean anti-Xa activities peaked abruptly at
2.1 IU/ml with 1 mg/kg enoxaparin and at 1.5 IU/ml with
0.75 mg/kg enoxaparin. Although abciximab was used
concomitantly in the NICE-4 study, the rate of major
bleeding using 0.75 mg/kg enoxaparin was lower than that
using 1 mg/kg enoxaparin in NICE-1. Sheath withdrawals
were delayed in both studies.
Studies have shown that target anti-Xa levels0.5 IU/ml
are effective for performing PCI while using enoxaparin, or
for treating UA (3,12,13). Data on the co-administration of
LMWH and GP IIb/IIIa inhibitors in PCI are rare and are
limited to the GP IIb/IIIa inhibitor abciximab (10,11). A
new dosing regimen of eptifibatide has recently been shown
to be effective in elective PCI (14), but data are needed on
eptifibatide’s concomitant use with LMWH. Considering
the available pharmacokinetic data obtained with IV enox-
aparin in healthy volunteers and the anti-Xa levels obtained
in previous PCI studies, we aimed at a dose giving a median
anti-Xa activity close to 1 IU, expecting then a Gaussian
distribution of anti-Xa levels with 95% of patients above 0.5
IU, just as in our previous study (3). On the basis of the
available data with enoxaparin (3,11–13), we hypothesized
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that an IV dose of enoxaparin of only 0.5 mg/kg could
provide adequate anticoagulation irrespective of patient
characteristics such as age, weight, renal function, or the use
of the GP IIb/IIIa inhibitor eptifibatide. Indeed, some
concerns have been raised about the safety of LMWH in
patients with renal failure because of their preferential
kidney elimination, and in obese patients because of possible
variations in subcutaneous resorption and volume distribu-
tion of these drugs. This unique and low dose of enoxaparin
would also offer the advantage of preventing excessive
anticoagulation following bailout prescription of GP IIb/
IIIa inhibitors, which is common in many centers. We also
expected that such a low dose of enoxaparin would improve
safety in all indications and allow immediate sheath re-
moval.
The aim of our study was to show that a single IV bolus
of 0.5 mg/kg enoxaparin in elective PCI would provide
adequate anticoagulation, defined as a peak anti-Xa level
0.5 IU/ml in 95% of patients (3), and would not cause
over-anticoagulation, defined as a peak anti-Xa level 1.5
IU/ml, in patients at increased risk of overdosage or bleed-
ing. These patients were defined as groups with renal
dysfunction, overweight, advanced age, or GP IIb/IIIa
inhibition (15–17). Ischemic end points were considered a
secondary objective of the study.
METHODS
Patient population. A total of 242 consecutive patients
admitted for elective PCI were enrolled in the study. All
patients were 18 years old and were referred for elective
PCI of a native or vein graft stenosis of 70%. Exclusion
criteria were primary PCI for ST-elevation MI, admission
to the cardiac care unit for initial medical therapy, LMWH
or UFH within the last 48 h before PCI, or a GP IIb/IIIa
antagonist within the previous two weeks. Renal dysfunc-
tion was defined as a calculated creatinine clearance of 40
ml/min (3), elderly was defined as age 75 years, and
overweight was defined as 100 kg. The study was ap-
proved by the Pitie´-Salpeˆtrie`re Ethical Committee for
Clinical Studies, and informed oral consent was obtained
from all patients.
Procedures for PCI. Percutaneous coronary intervention
was performed immediately after a coronary angiogram
using standard techniques, the femoral approach, and 6F
guiding catheters in all patients. Sheaths were removed with
manual or pneumatic compression (FemoStop II plus, Radi
Medical Systems, Uppsala, Sweden) immediately after PCI
when eptifibatide was not used (n  178), or 4 h later when
PCI was performed with eptifibatide (n  64). Vascular
closure devices were not used. Patients were allowed to walk
on the next morning (bed-rest time 12 h) and left the
hospital on the same day.
Study medications. Intravenous enoxaparin, 0.5 mg/kg
single IV bolus, was used in all patients due to undergo PCI
irrespective of the age or renal function of the patient or the
use of GP IIb/IIIa inhibitors. There was no weight-related
upper limit for the dose of enoxaparin. Percutaneous coro-
nary intervention was performed without the administration
of UFH or an additional bolus of enoxaparin, and no
antithrombin treatment was administered after the proce-
dure. There was no on-site monitoring of coagulation either
during or after the procedure. Sheaths and catheters were
flushed with a saline solution containing 23 mg/l of enox-
aparin. All patients received a loading dose of aspirin (500
mg IV) before the start of the procedure, followed by a daily
dose of 75 to 300 mg. Clopidogrel (300 mg) was adminis-
tered immediately after stenting, except to patients who had
previously received clopidogrel (n  22), and then 75
mg/day was administered for one month. Eptifibatide was
the only GP IIb/IIIa inhibitor used in this study. A first
bolus of 180 g/kg eptifibatide was given simultaneously
with the enoxaparin bolus, and a 2.0 g/kg/min continuous
infusion was started immediately and continued for 18 h. A
second 180 g/kg eptifibatide bolus was given 10 min after
the first bolus and just before the start of the procedure.
Biologic measurements. Serial blood samples were taken
to measure anti-Xa activity: before the IV bolus of enox-
aparin, 10 min after the bolus (start of PCI), at the end of
the PCI, 3 h after the PCI, and on the morning after PCI.
Blood was collected into vacutainer tubes (Vacutainer,
Becton Dickinson, Plymouth, United Kingdom) containing
0.129 M trisodium citrate. Platelet-poor plasma was ob-
tained by centrifugation at 3,500 g at 10°C for 20 min.
Plasma anti-Xa activity was determined by an amidolytic
assay using the specific chromogenic substrate CBS 52.44
and bovine factor Xa as reagents and STA analyzers
(Diagnostica Stago, Asnie`res, France). Activated partial
thromboplastin time (aPTT) was measured using Auto-
mated aPTT (Organon Teknika Corporation, Durham,
North Carolina), and anti-IIa activity was measured using
an indirect method based on the plasma thrombin clotting
Abbreviations and Acronyms
ACT  activated clotting time
aPTT  activated partial thromboplastin time
CI  confidence interval




LMWH  low-molecular-weight heparin
MI  myocardial infarction
NICE  National Investigators Collaborating on
Enoxaparin
NSTEMI  non–ST-elevation myocardial infarction
PCI  percutaneous coronary intervention
PEPCI  Pharmacokinetic study of Enoxaparin in
Patients undergoing Coronary Intervention
TIMI  Thrombolysis In Myocardial Infarction
UA  unstable angina
UFH  unfractionated heparin
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time. The coefficients of variation for aPTT, anti-Xa, and
anti-IIa assays were all 5%.
Troponin-I levels were determined by a fluorogenic
enzyme-linked immunoassay using a monoclonal antibody
and OPUS-PLUS analyzers (Dade-Behring SA, Paris La
De´fense, France). Levels of troponin-I and creatine kinase
(CK) were measured before PCI, 3 h after PCI, and on the
morning (approximately 18 h) after PCI. In case of recur-
rent ischemia, troponin-I and CK levels were measured
again every 6 h and throughout the following 24 h. A
troponin-I level 2 g/ml within 24 h of PCI was
considered as a periprocedural MI, even if the level of CK
was normal.
In all patients, platelet counts were measured before and
after PCI, and in patients receiving eptifibatide, platelet
counts were repeated 1, 4, and 24 h after the bolus
administration. Thrombocytopenia was defined as a platelet
count of 50,000 or as a decrease of 50% from the previous
platelet count.
Clinical follow-up. In-hospital follow-up was based on
physical examination, electrocardiogram (ECG), and CK
and troponin-I levels. All patients in this study were
followed up at one month by written questionnaires or
telephone interviews. Information obtained was relative to
living status, rehospitalization, reinfarction, subsequent car-
diac catheterization or revascularization, and any form of
bleeding. In case of an event during follow-up, more
information was sought from hospital records and inter-
views with physicians. The outcome end point was defined
as a composite of death, myocardial infarction (MI), and
urgent target vessel revascularization. Myocardial infarction
was defined as recurrent chest pain and/or ECG changes
with at least one of the following: troponin-I positive, with
levels of CK 2 times the upper limit of normal and an
increase of50% of the previous value, or the appearance of
a new left bundle branch block or new Q waves. Urgent
revascularization was defined as urgent PCI or coronary
artery bypass grafting necessitated by recurrent ischemia of
the target vessel. Bleeding definitions were adapted from the
Thrombolysis In Myocardial Infarction (TIMI) criteria.
Major hemorrhage corresponded to: 1) bleeding resulting in
death or requiring surgery; 2) a bleed in an intracranial or
intraocular location; or 3) a drop in the serum concentration
of hemoglobin 5 g/dl (or 15% of the hematocrit value).
Minor bleeding was any clinically important bleeding that
did not qualify as major or that was not clinically identified
but associated with a drop in the serum hemoglobin
concentration 4 g/dl (or 12% of the hematocrit level).
Statistics. The percentage of patients with a peak anti-Xa
activity 0.5 IU/ml and 1.5 IU/ml was calculated for the
overall patient population and for the predefined subgroups.
Simple linear regression was used to test the association
between continuous variables. Potential associations be-
tween clinical and biologic parameters were tested by
univariate procedures using the Student t or chi-square test.
Results are expressed as mean SD. The alpha level was set
at 0.05.
RESULTS
Patient characteristics. A total of 242 consecutive pa-
tients, who underwent elective PCI to treat 303 coronary
lesions, were enrolled in the study. Table 1 shows the
patients’ baseline and angiographic characteristics.
Multiple-vessel angioplasty was performed in 56 patients
(23%). Most of the coronary lesions that were treated were
in class B (54%) or C (23%) of the American College of
Cardiology/American Heart Association classification. A
stent was implanted in 169 of the 233 de novo lesions
(72%). The decision to implant a stent or prescribe eptifi-
batide was made at the discretion of the physician. Admin-
istration of eptifibatide was always begun before PCI (n 
64, 26%); no bailout prescription of GP IIb/IIIa inhibitors
occurred in the patients not originally administered eptifi-
batide (n  178).
Anticoagulation during and after PCI. A peak anti-Xa
0.5 IU/ml was obtained in 97.5% of patients, and 94.6%
of patients had a peak anti-Xa level in the target range of 0.5
to 1.5 IU/ml. Effective levels of anticoagulation were ob-
tained 10 min after the administration of the enoxaparin
bolus corresponding to the start of procedure: the mean
anti-Xa activity was 0.88  0.31 IU/ml (Table 2, Fig. 1A).
Anti-Xa activity was stable throughout the procedure,
confirming a high and constant degree of anticoagulation
(Table 2, Fig. 1B). Throughout the procedure (as detected
by two coagulation measurements, at the start and the end
of the procedure), the anti-Xa activity remained 0.5
Table 1. Baseline Clinical Characteristics of Enrolled Patients
Age, yrs 64  11*
Age 75 yrs, n (%) 33 (14)
Men, n (%) 190 (78)
Body mass index, kg/m2 27  5*
Overweight (100 kg), n (%) 21 (9)
Creatinine clearance, ml/min 70  28*
Creatinine clearance 40 ml/min, n (%) 30 (12)
Left ventricular ejection fraction, % 62  13*
Risk factors, n (%)
Smoking 50 (21)
History of hypercholesterolemia 159 (66)
Hypertension 146 (60)
Diabetes mellitus 84 (35)
Previous MI (1 month) 76 (31)
Recent MI (1 month) 4 (2)
Previous coronary angioplasty 95 (39)
Previous coronary bypass 29 (12)
Peripheral vascular disease 36 (15)
Previous stroke 19 (8)
Target vessel of PCI, n (%)
Left anterior descending coronary artery 116 (39)
Left circumflex coronary artery 75 (25)
Right coronary artery 94 (32)
Saphenous vein graft 11 (4)
Left main 1 (0.4)
*Mean value  SD.
MI  myocardial infarction; PCI  percutaneous coronary intervention.
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IU/ml in only 6 patients (2.5%), was 1 IU/ml in 27
patients (11.1%), and did not exceed 1.5 IU/ml in any
patient. This unique dose of enoxaparin provided similar,
safe levels of anti-Xa activity in the patient subgroups
considered to have an increased risk of bleeding (Table 3).
The percentage of patients who were not over-
anticoagulated (peak anti-Xa activity 1.5 IU/ml) was
similar in the elderly versus the non-elderly subgroups (97%
in both, p  0%, confidence interval [CI] 5 to 5%), in
patients with versus without renal dysfunction (100% vs.
97%, p  3.5%, CI 1 to 5.5%), and in overweight versus
nonoverweight patients (95% vs. 97%, p  2%, CI 10
to 6%). No significant relationships were found between
anti-Xa activity and creatinine clearance or weight. No
interaction was found between smoking status and anti-Xa
activity at any of the five time points.
No difference in anti-Xa activity was observed between
patients treated with enoxaparin alone and those who
received enoxaparin and eptifibatide (Fig. 2). The propor-
tion of patients with a peak anti-Xa activity1.5 IU/ml was
very similar whether eptifibatide was used or not used (98%
vs. 96%, p  2%, CI 1.5 to 5%).
The aPTT and anti-IIa activity increased significantly
after the administration of the enoxaparin bolus, as shown
in Table 2. The prolongation of aPTT measured here is in
concordance with previous studies using IV injections of
enoxaparin (9,10). Finally, no patient developed thrombo-
cytopenia.
Clinical outcomes at day 30. Follow-up was obtained in
all patients. Table 4 shows the incidence of the composite
end point of death, MI, or urgent target vessel revascular-
ization and of each of its components, as well as the
incidence of major and minor bleeding. None of the
ischemic or bleeding events correlated with the levels of
anti-Xa activity measured at any of the time points. Four
days after the PCI, one patient developed an out-of-
laboratory abrupt closure with ST-segment elevation be-
cause of a coronary dissection. After receiving abciximab,
the patient underwent unsuccessful urgent revascularization
and died suddenly eight days later. Two patients had
nonfatal non–Q-wave MI: one case was related to a coro-
nary dissection treated by stent implantation on day 4, and
the other case was a result of a side-branch occlusion with
no angiographic complication of the target vessel. The five
patients who underwent urgent revascularization had a
coronary dissection on the angiogram. Importantly, all six
patients with an ischemic complication had anti-Xa levels
0.5 IU/ml from the beginning to the end of the procedure.
We also examined the patients who had no clinical
ischemic complications or significant increase in CK but
had increased troponin-I levels, detected by serial measure-
ments during the first 24 h after PCI (2 g/ml, n  21).
In these patients, the mean anti-Xa activity was 0.84 0.09
IU/ml at the start of PCI and 0.81 0.04 IU/ml at the end,
and was similar to mean anti-Xa activity in patients with
negative troponin-I levels. The global rate of both MI and
periprocedural MI was 10% in this study.
The only case of major bleeding was a groin hematoma
with a false aneurysm in an 82-year-old woman who was
treated with eptifibatide, which necessitated a transfusion of
two units of blood and urgent vascular surgery. This
patient’s anti-Xa activity was 0.90 IU/ml at the beginning
of, 0.92 IU/ml at the end of, and 0.54 IU/ml 3 h after the
procedure. Three other patients had minor bleeding com-
plications (groin hematomas).
DISCUSSION
Our data strongly suggest that a single IV bolus of 0.5
mg/kg enoxaparin is feasible in elective PCI. This reduced
dose allows reaching the prespecified level of anticoagula-
tion without dose adjustment or coagulation monitoring,
which simplifies anticoagulation management during the
procedure; allows immediate sheath removal when PCI is
performed with enoxaparin alone; and provides similar
anticoagulation and safety in patients irrespective of ad-
vanced age, renal dysfunction, being overweight, or the use
of a double bolus of eptifibatide. No thrombocytopenia was
observed in this group of patients. The few periprocedural
ischemic events observed were not related to low anti-Xa
levels but mainly to coronary dissections.
Unfractionated heparin has been the primary anticoagu-
lant therapy for PCI for more than 20 years, but the optimal
dose and the ideal target activated clotting time (ACT)
remain uncertain and controversial (6,18). The low bioavail-
ability, unpredictable anticoagulant response, activation of
platelets, unsatisfactory correlations between measurements
of ACT and aPTT, device-to-device variations in ACT
measurements, and the lack of net prospective evaluations to
correlate ACT measurements to clinical outcomes associ-
ated with UFH have led to empirical recommendations for
both UFH doses and ACT target values. However, the
most recent recommendations recognize the possible need
for lower doses of UFH than before, even in the absence of
GP IIb/IIIa inhibitors (6).
Although LMWH does not have the same disadvantages
as UFH, the ideal regimen for its use in PCI is yet to be
determined. However, the predictable anticoagulant re-
sponse following a single IV dose of LMWH suggests that








Before enoxaparin bolus 0.07  0.08 35  4 0.05  0.09
Start of PCI 0.88  0.31 86  23 0.37  0.12
End of PCI 0.83  0.26 64  17 0.26  0.1
3 h after PCI 0.47  0.19 42  11 0.11  0.09
18 to 24 h after PCI 0.07  0.08 35  9 0.02  0.05
*Mean values  SD.
aPTT  activated partial thromboplastin time; PCI  percutaneous coronary
intervention.
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neither dose adjustments nor on-site coagulation monitor-
ing are necessary (19). The safety profile of a single IV bolus
of LMWH should be even better than that of the repeated
subcutaneous injections evaluated in UA trials (1,2,20). The
risk of overdose with a single IV dose is not related to the
degree of subcutaneous resorption, and should be much less
dependent on renal function (15,21). In addition to the
pharmacologic benefits and enhanced ratio of anti-Xa:anti-
IIa activity of LMWH over UFH, other positive effects
include more effective release of tissue factor pathway
inhibitor and blunting of von Willebrand factor release, a
rise of which is associated with poor outcomes in UA
Figure 1. Distribution of anti-Xa activity levels at the beginning (A) and end (B) of percutaneous coronary intervention.
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(22,23). More recently, both the release of von Willebrand
factor and changes in platelet GP Ib/IX complexes (recep-
tors for von Willebrand factor) have been shown to predict
adverse outcomes in UA, and both were affected favorably
by enoxaparin (24).
Our initial hypothesis that there would be no differences
in the anti-Xa levels during elective PCI in patients at
increased risk of overdosage or bleeding has been verified in
all the high-risk subgroups. Although reassuring, the data
obtained in obese and renal failure patients would deserve
further confirmation; however, the similar degrees of anti-
coagulation that we have shown among these subgroups
strongly suggest that this dose has a good safety and efficacy
profile across all clinical indications. One unique dose that
can be used in all patients whatever their age, weight, renal
function, and use or not of GP IIb/IIIa inhibitors offers
obvious practical advantages to medical staff. The concept of
a unique dose may also yield safety advantages, owing to the
simplification of the dosing regimen and subsequent reduc-
tion in the risk of dosing errors.
The optimal anti-Xa target has not yet been precisely
evaluated and may differ with various LMWHs. Most
experience (although limited) has been obtained with enox-
aparin (9,11,12). In UA, 1 mg/kg subcutaneous enoxaparin
every 12 h (tested in TIMI 11A (13), then used in TIMI
11B (2) was associated with mean anti-Xa levels of 1.0
IU/ml (peak) and 0.5 IU/ml (trough). In patients with UA
receiving 1 mg/kg subcutaneous enoxaparin, peak anti-Xa
activities were close to 1.2 IU/ml in the Pharmacokinetic
study of Enoxaparin in Patients undergoing Coronary
Intervention (PEPCI) (12) and close to 1 IU/ml in our
previous study (3).
In the present study, we selected an IV dose that would
reproduce levels of anticoagulation similar to those obtained
using subcutaneous injection: a peak anti-Xa level 0.5
IU/ml in 95% of patients, a median close to 1 IU/ml, and
an upper limit of 1.5 IU/ml for safety considerations. A peak
anti-Xa 0.5 IU/ml was obtained in 97.5% of patients
(97.6% in the previous study) (3). The majority of patients
were close to 1 IU/ml, as shown in Figures 1 and 2.
Table 3. Levels of Anti-Xa Activity in Patients Undergoing PCI, According to Age, Renal Failure, and Weight
Age, yrs Creatinine Clearance, ml/min Weight, kg
<75 >75 >40 <40 <100 >100
(n  209) (n  33) (n  212) (n  30) (n  221) (n  21)
Before enoxaparin bolus 0.07  0.08 0.08  0.08 0.06  0.07 0.07  0.07 0.07  0.08 0.05  0.04
Start of PCI 0.90  0.32 0.75  0.19 0.88  0.32 0.88  0.23 0.88  0.31 0.88  0.26
End of PCI 0.87  0.26 0.71  0.21 0.83  0.27 0.79  0.18 0.82  0.26 0.91  0.24
3 h after PCI 0.48  0.19 0.43  0.12 0.46  0.19 0.51  0.12 0.46  0.15 0.57  0.41
18 to 24 h after PCI 0.07  0.08 0.06  0.06 0.06  0.07 0.13  0.12 0.07  0.07 0.11  0.13
*Mean value  SD.
PCI  percutaneous coronary intervention.
Figure 2. Anti-Xa activity levels before, during, and after percutaneous coronary intervention (PCI), with the use (open circles) and nonuse (closed circles)
of eptifibatide.
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Interestingly, the peak anti-Xa levels were 2.1  0.7 IU/ml,
1.5  0.6 IU/ml, and 0.9  0.3 IU/ml in the NICE-1,
NICE-4, and present study, respectively, and the incidences
of major and minor bleeds were 6.1%, 7.0%, and 1.6%,
respectively. These data suggest that bleeding may well
increase with anti-Xa levels above 1.5 IU/ml. The study of
Kereiakes et al. (10) using a low dose of dalteparin (60
IU/kg, n  76) produced a similar anti-Xa profile (peak at
0.8 IU/ml) and similarly few bleedings as the present study.
The lack of a relationship between the occurrence of
ischemic events or periprocedural MI and periprocedural
anti-Xa levels, as well as the low incidence of ischemic
events in the present study when compared with other PCI
trials, indicate the need for further evaluation of this low
dose of enoxaparin (11,14,17,25–27).
In contrast with the NICE-1 study, the reduced dose of
enoxaparin used here allowed safe immediate sheath with-
drawal with manual compression, favoring expeditive care
for these elective cases. In the present study, the average
anti-Xa level was 0.83  0.26 IU/ml when we removed the
sheath immediately after the procedure, a level similar to
that measured 4 h after PCI in NICE-1 at the time of
sheath removal (0.8  0.3 IU/ml). The combination of this
low dose of enoxaparin with the successfully tested high
dose of eptifibatide proved to be safe on the basis of
anticoagulation levels and clinical outcomes (14). Following
usual recommendations (14,17) for the use of GP IIb/IIIa
inhibitors, sheath withdrawal was delayed for 4 h in patients
receiving eptifibatide, allowing a new check of platelet
count. It remains to be shown whether immediate sheath
withdrawal is also possible in these patients. Finally, the use
of both enoxaparin and eptifibatide should considerably
decrease the risk of thrombocytopenia compared to UFH
and abciximab, and indeed, no case of thrombocytopenia
was observed in this study (28,29).
Clearly, our study is not sized or designed to draw any
definite conclusion on the use of this low dose of enoxapa-
rin. However, in the actual preliminary phase that evaluates
the optimal anticoagulation target with enoxaparin in PCI,
our study provides the first evaluation of a low dose of IV
enoxaparin in nonselected patients. These data may aid the
design of future randomized trials comparing LMWH with
UFH in PCI. All the criteria for safety measured (target
levels of anticoagulation, use in high-risk patient subgroups,
administration of GP IIb/IIIa inhibitors, early sheath with-
drawal, occurrence of thrombocytopenia) were favorable for
this low, unique dose of enoxaparin.
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